title: Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women.
abstract: BACKGROUND
  Calcium channel antagonist therapy in humans has been associated with changes in anterior pituitary, thyroid and adrenal hormone secretion. Human studies assessing effects of calcium channel antagonists on calciotropic hormones have been few and typically involved small numbers of subjects studied for short periods of time. Few of these previously published studies have included women. The endocrine effects of calcium channel antagonists in women have become increasingly important as more women are taking these agents for diseases such as hypertension, angina, Raynaud's phenomenon and migraine.
  
  
  OBJECTIVE
  To assess both acute and chronic effects of calcium channel antagonists on calciotropic hormones in women.
  
  
  METHODS
  A four-week prospective, randomized trial.
  
  
  METHODS
  Twenty-nine premenopausal women, randomly assigned to receive either 240 mg of sustained release verapamil or 30 mg of sustained release nifedipine daily. LABORATORY END-POINTS: Total and ionized serum calcium, phosphate, creatinine, parathyroid hormone (PTH), parathyroid hormone-related protein (PTHrP) and calcitonin, measured at baseline, after 24 hours, and 28 days of treatment.
  
  
  RESULTS
  Total and ionized calcium, phosphate, creatinine, PTHrP and calcitonin levels were not altered significantly after 24 hours or 28 days in any of the subjects, when compared to baseline. There were no significant differences in PTH levels after 24 hours or 28 days of verapamil treatment. There was a significant increase in serum PTH levels after 24 hours of nifedipine therapy; however, these differences were not evident after 28 days of therapy.
  
  
  CONCLUSIONS
  The short-term administration of nifedipine results in increased release of parathyroid hormone; however, long-term administration has no significant effect on the concentrations of calciotropic hormones.
authors.affiliation: Department of Medicine, Mayo Clinic, Rochester, MN 55905.
authors.forename: A G
authors.initials: AG
authors.lastname: Wynne
authors.forename: S A
authors.initials: SA
authors.lastname: Romanski
authors.forename: G G
authors.initials: GG
authors.lastname: Klee
authors.forename: S J
authors.initials: SJ
authors.lastname: Ory
authors.forename: W M
authors.initials: WM
authors.lastname: O'Fallon
authors.forename: L A
authors.initials: LA
authors.lastname: Fitzpatrick
mesh_terms: D000328:Adult; D002116:Calcitonin / Q000097:blood; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008875:Middle Aged; D009543:Nifedipine / Q000494:pharmacology*; D010281:Parathyroid Hormone / Q000097:blood*; D044162:Parathyroid Hormone-Related Protein; D017697:Premenopause / Q000097:blood*; D011446:Prospective Studies; D011506:Proteins / Q000378:metabolism; D013997:Time Factors; D014700:Verapamil / Q000494:pharmacology*
chemical_list: D003692:Delayed-Action Preparations; C470121:PTHLH protein, human; D010281:Parathyroid Hormone; D044162:Parathyroid Hormone-Related Protein; D011506:Proteins; D002116:Calcitonin; D003404:Creatinine; D014700:Verapamil; D009543:Nifedipine; D002118:Calcium